Search

everythinglearnresearchcommunity

for

Search:↓

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.

The effect of GLP-1 RAs on erectile function is unclear and needs more research.

Community pharmacies and pharmacists play a crucial role in improving community health.

Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.

Semaglutide may help some skin disorders but can also cause skin issues.

Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.

Semaglutide may worsen eating disorders in vulnerable individuals.

Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

GLP-1 agonists may increase the risk of hair loss.

Semaglutide does not significantly increase the risk of hair loss.

The model and estimator can predict drug exposure in kidney transplant patients well.

Semaglutide helps obese PCOS patients lose weight and improve health.

Weight-loss drugs are not linked to suicidal thoughts.

Newer GLP-1 drugs like semaglutide may cause hair loss.

Semaglutide may cause hair loss, but more research is needed to confirm this.

A rash from semaglutide may be due to propylene glycol, not the drug itself.

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.

GLP-1RA therapy may increase the risk of hair loss.

GLP-1 agonists may help treat certain skin conditions.

GLP-1 receptor agonists may cause hair loss, but more research is needed.

Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.